---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-062047"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:29:54.694880+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics receives Nasdaq delisting notice; hearing set for June 25, 2024

## Summary
- Nasdaq delisting notice due to failure to maintain minimum $1.00 bid price for 30 consecutive business days.
- Company not eligible for second compliance period due to failure to meet $5M stockholders' equity requirement for initial listing.
- Appealed delisting on May 14, 2024; delisting stayed pending final written decision after hearing on June 25, 2024.
- Stock continues to trade on Nasdaq under symbol RNAZ; no assurance appeal will be successful.

## SEC filing metadata
- accession: 0001104659-24-062047
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924062047/0001104659-24-062047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924062047/tm2414638d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-062047
- JSON: https://secwatch.observer/filing/0001104659-24-062047.json
- Plain text: https://secwatch.observer/filing/0001104659-24-062047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.